Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Jefferies said the '$1.0 billion upfront acquisition of Clementia should be well received,' but the piece flagged a failed midphase study raising efficacy…
FDA placed palovarotene on partial clinical hold in pediatric FOP patients citing premature growth plate closure, an early setback to Ipsen's $1.04B Clementia…
Four years and multiple regulatory setbacks after the $1.3B Clementia deal, palovarotene finally won FDA approval as Sohonos for FOP — though the MO indication…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Ipsen agreed to acquire Clementia for up to $1.31B, comprising $1.04B upfront ($25/share) plus a CVR of $6/share (~$263M) tied to acceptance of palovarotene NDA filing. Adds rare bone disease assets including palovarotene for fibrodysplasia ossificans progressiva and multiple osteochondromas.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ipsen S.A. / Clementia Pharmaceuticals Inc. (this deal) | 2019 | $1.3B | — |
| Ipsen S.A. / Exelixis Inc. | 2016 | $855M | 80 |
| Ipsen S.A. / Kartos Therapeutics, Inc. | 2026 | $1.8B | 68 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Ipsen S.A. / Marengo Therapeutics, Inc. | 2024 | $1.2B | — |
| Ipsen S.A. / GENFIT | 2021 | $543M | — |
| Ipsen S.A. / Simcere Zaiming Pharmaceutical Co., Ltd. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2019 deals · Ipsen S.A. deals · Rare Disease deals